Repligen

Yahoo Finance • yesterday

Barclays Maintains an “Overweight Rating” on Repligen Corporation (RGEN)

Repligen Corporation (NASDAQ:RGEN) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen. On May 7, Barclays raised Repligen Corporation (NASDAQ:RGEN)’s price goal to $160 from $145. It maintained an “Ove... Full story

Yahoo Finance • 7 days ago

Repligen (RGEN) Q1 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, May 5, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Olivier LoeillotChief Financial Officer — Jason Garland TAKEAWAYS Revenue -- $194 million reported, representing 15% gr... Full story

Yahoo Finance • 8 days ago

Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-yearReiterating FY26 organic revenue growth guidance of 9%-13... Full story

Yahoo Finance • 16 days ago

Tempered Forward Expectations Hurt Repligen Corp. (RGEN) in Q1

Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive... Full story

Yahoo Finance • 23 days ago

Here’s What Positioned Repligen Corporation (RGEN) for a Durable Long-Term Growth

Fred Alger Management, an investment management company, released its “Alger Mid Cap Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter of 2026, Class A shares of the Alger Mid Cap F... Full story

Yahoo Finance • 26 days ago

Apple upgraded, Qualcomm downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: BNP Paribas upgraded Apple (AAPL) to O... Full story

Yahoo Finance • 29 days ago

1 Cash-Producing Stock Worth Your Attention and 2 We Avoid

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. Not all companies are created equal, a... Full story

Yahoo Finance • 2 months ago

RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as investors reacted to escalating uncertainty tied to the U.S.-Iran conflict and poli... Full story

Yahoo Finance • 2 months ago

2 Growth Stocks Set to Flourishand 1 We Turn Down

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. The risks that can come from buying these asse... Full story

Yahoo Finance • 2 months ago

Signatera Oncology Test Drives Natera’s (NTRA) Growth

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter can be downloaded here. The fourth quarter of 2025 saw mixed res... Full story

Yahoo Finance • 2 months ago

Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key measure of inflation at... Full story

Yahoo Finance • 3 months ago

How The Repligen (RGEN) Narrative Is Shifting With New Targets M&A Plans And Products

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The updated fair value for Repligen is set at US$190.89, with analysts treating this as a recali... Full story

Yahoo Finance • 3 months ago

Repligen (RGEN) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Feb. 24, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Olivier Loeillot Chief Financial Officer — Jason Garland Vice President, Investor Relations — Jacob Jo... Full story

Yahoo Finance • 3 months ago

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported an... Full story

Yahoo Finance • 3 months ago

Repligen Corp. (RGEN) Rose as Industrial Destocking Decreased and Order Patterns Stabilized

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2025 investor letter. As many believe, US equities experienced solid returns in 2025, with double-digit gains across all major indices, yet underlying con... Full story

Yahoo Finance • 3 months ago

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Repligen Corporation Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its... Full story

Yahoo Finance • 3 months ago

Repligen is Now Oversold (RGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 5 months ago

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Repligen Corporation WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan... Full story

Yahoo Finance • 6 months ago

Repligen Corporation to Present at Evercore Healthcare Conference

WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate in the 8th Annual Evercore Healthca... Full story

Yahoo Finance • 6 months ago

Three Companies Estimated To Be Priced Below Their Intrinsic Value In November 2025

As the Dow Jones Industrial Average reaches new heights amid optimism surrounding a potential end to the U.S. government shutdown, investors are closely watching market fluctuations with mixed performances across major indices. In this env... Full story